Cyclophilin A modulates processing of human immunodeficiency virus type 1 p55(Gag): Mechanism for antiviral effects of cyclosporin A

Virology

Volumn 245, Issue 2, 1998, Pages 197-202

  Streblow, Daniel N ^a   Kitabwalla, Moiz ^a   Malkovsky, Miroslav ^a   Pauza, C David ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; CYCLOSPORIN A;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN COS1; DRUG POTENCY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRION; VIRUS INHIBITION;

HIV 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE; RNA VIRUSES;

EID: 0032486259     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9155     Document Type: Article

References (25)

1. Aberham C., Weber S., Phares W. Spontaneous mutations in the human immunodefiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J. Virol. 70:1996;3536-3544.
2. Barré-Sinoussi F., Cherman J., Rey R., Nugeryre S., Chamaret S., Gruest J., Rosenbaum W., Montagnier L. Isolation of T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:1983;868-871.
3. Bartz S. R., Hohenwalter E., Hu M. K., Rich D. H., Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. USA. 92:1995;5381-5385.
4. Braaten D., Aberham C., Franke E. K., Yin L., Phares W., Luban J. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that gag encodes the functional target of cyclophilin A. J. Virol. 70:1996;5170-5176.
5. Braaten D., Franke E. K., Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70:1996;3551-3560.
6. Colgan J., Yuan H. E. H., Franke E. K., Luban J. Binding of the human immunodeficiency virus type 1 gag polyprotein to cyclosporin A is mediated by the central region of capsid and requires gag dimerization. J. Virol. 70:1996;4299-4310.
7. Deng H., Wang C., Acsadi G., Wolff J. High-efficiency protein synthesis from T7 RNA polymerase transcripts in 3T3 fibroblasts. Gene. 109:1991;193-201.
8. Elroy-Stein O., Fuerst T., Moss B. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid system. Proc. Natl. Acad. Sci. USA. 86:1989;6126-6130.
9. Franke E. K., Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the gag-cyclophilin A interaction. Virology. 222:1996;279-282.
10. Franke E. K., Yuan H. E. H., Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 372:1994;359-362.
11. Friedman J., Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA. Cell. 66:1991;799-806.
12. Gitti R. K., Lee B. M., Walker J., Summers M. F., Yoo S., Sundquist W. I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science. 273:1996;231-235.
13. Handschumacher R. E., Harding M. W., Rice J., Drugge R. J., Speicher D. W. Cyclophilin A: A specific cytosolic binding protein for cyclsporin A. Science. 226:1984;544-547.
14. Karpas A., Lowdell M., Jacobson S. K., Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc. Natl. Acad. Sci. USA. 89:1992;8351-8355.
15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Anal. Biochem. 227:1970;680.
16. Luban J., Bossolt K. L., Franke E. K., Kalpana G. V., Goff S. P. Human immunodeficiency virus type 1 gag protein binds to cyclophilins A and B. Cell. 73:1993;1067-1078.
17. McCaffery P. G., Perrino B. A., Soderling T. R., Rao A. NF-ATp, a T-lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J. Biol. Chem. 268:1993;3747-3752.
18. Ott D., Coren L., Johnson D., Sowder R., Arthur L., Henderson L. Protein analysis of immunophilins found in Human and Simian immunodeficiency viruses. AIDS Res. Hum. Retroviruses. 11:1995.
19. Rich D., Prasad V., Sun C., Green J., Mueller R., Houseman K., MacKenzie D., Malkovsky M. New hydroxyethylamine HIV protease inhibitors that suppress viral replication. J. Med. Chem. 35:1992;3803-3812.
20. Rose J., Babe L., Craik C. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69:1995;2751-2758.
21. Rosenwirth B., Billich A., Datema R., Donatsch P., Hammerschmid F., Harrison R., Hiestand P., Jaksche H., Mayer P., Peichl P., Quesniaux V., Schatz R., Schuurman H., Traber R., Wenger R., Wolff B., Zenke G., Zurini M. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 38:1994;1763-1772.
22. Schmid F. X. Prolyl isomerase: Enzymatic catalysis of slow protein-folding reactions. Annu. Rev. Biophys. Biomol. Struct. 22:1993;123-143.
23. Thali M., Bukovsky A., Kondo E., Rosenwirth B., Walsh B. T., Sodroski J., Göttlinger H. G. Functional association of cyclophilin A with HIV-1 virions. Nature. 372:1994;363-365.
24. Traber R., Kobel H., Loosli H., Senn H., Rosenwirth B., Lawen A. [Melle4]Cyclosporin, a novel natural cyclosporin with anti-HIV activity: Structural elucidation, biosynthesis, and biological proterties. Antiviral Chem. Chemother. 5:1994;331-339.
25. Wainberg M. A., Dascal A., Blain N., Fitz-Gibbon L., Boulerice F., Numazaki K., Tremblay M. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood. 72:1988;1904-1910.